The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

PRNewswire Bangalore Karnataka [India] January 15 Manipal Hospitals Sarjapur Road recently hosted an awareness session on ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Drug treatment of BPH was initially viewed with suspicion by urologists, but has gradually achieved widespread acceptance, with excellent consequences for patients. Urologists had further ...

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive ... on pharmacological therapy for benign prostatic hyperplasia (BPH).

Debruyne et al. [69] conducted a multicenter, randomized study of 1051 patients with BPH. Patients received ER alfuzosin 5 mg twice daily, finasteride 5 mg daily, or both drugs for six months.

In this video, Wayne Kuang, MD, discusses the importance of collaborating with other health care professionals when treating benign prostatic hyperplasia (BPH). Kuang is a urologist and CEO of the MD ...

In honor of the final week of Men's Health Month, Dr. Kevin McVary joins the Urology Care Podcast to discuss new and emerging treatment options for Benign Prostatic Hyperplasia (BPH). Dr. McVary is a ...

Should antifibrotics prove to be a safe, effective treatment for prostate fibrosis and BPH, it could give millions of patients a new – and noninvasive – option for managing frustrating symptoms.